The Global Shift in Cannabis Policy by data: Insights from the US and Germany

The US Perspective: Rescheduling Cannabis

The proposal to reschedule cannabis from Schedule I to Schedule III in the United States marks a significant shift in federal drug policy. Historically, Schedule I drugs are classified as having a high potential for abuse and no accepted medical use, making them illegal to prescribe under federal law. Cannabis has long been lumped into this category, alongside drugs like heroin and LSD.

However, the Drug Enforcement Administration (DEA) has recently adopted a different approach in analyzing cannabis. This shift is partly driven by the proliferation of state-level medical cannabis programs, which have provided a wealth of data on cannabis use, effects, and safety. In contrast to its 2016 stance, the DEA now acknowledges that cannabis has a comparatively lower potential for abuse.

This rescheduling proposal is not merely a bureaucratic adjustment; it reflects a broader recognition of the changing public and scientific understanding of cannabis. It also underscores the power of grassroots movements in shaping federal policy. States’ defiance of federal regulations and the establishment of medical cannabis programs have played a crucial role in this shift, demonstrating how local actions can drive national change.

Despite potential political motivations, such as President Biden’s interest in appealing to a broader voter base, this policy shift has profound implications. Rescheduling cannabis to Schedule III would allow for more comprehensive research and potentially increase the number of doctors willing to prescribe cannabis, as they would no longer be violating federal law. However, it raises a critical question: Will doctors be more inclined to prescribe cannabis products that are not FDA-approved, despite the change in legal status?

Furthermore, concerns about youth marijuana use remain a significant point of debate. A study published in JAMA Psychiatry (April 24, 2024) examined the impact of recreational marijuana laws (RMLs) on youth marijuana use from 1993 to 2021. Using data from the Youth Risk Behavior Surveys (YRBS) and the interaction-weighted estimator, which accounts for heterogeneous and dynamic treatment effects, the study found that while legalization for individuals aged 21 and older is increasing, youth marijuana use still poses potential risks to health and academic performance .

The German Perspective: Legalization and Data Collection

On the other side of the Atlantic, Germany has taken a bold step by legalizing cannabis. This move aligns with a broader trend in Europe towards more lenient cannabis regulations. However, Germany’s approach is particularly noteworthy due to its emphasis on data collection from consumers.

The German government is actively gathering data on cannabis use, which serves multiple purposes. First, it helps in creating informed and effective national policies. More importantly, this data collection effort provides valuable insights that can assist other European Union (EU) countries in considering their own regulatory frameworks for cannabis.

Germany’s legalization and data-driven approach offer a model for other countries contemplating similar moves. By systematically studying the impacts of cannabis use and regulation, Germany is contributing to a growing body of evidence that can inform global cannabis policies.

The Global Impact

The developments in the US and Germany highlight a significant shift in the global perspective on cannabis. These changes are not happening in isolation but are part of a broader movement towards reevaluating the status and regulation of cannabis worldwide.

For other countries, these examples provide valuable lessons. The US experience underscores the importance of grassroots movements and the potential for state-level actions to influence federal policy. Germany’s approach emphasizes the value of data-driven policy-making and international collaboration.

As more countries consider changes to their cannabis regulations, the experiences of the US and Germany will likely serve as important reference points. By learning from these examples, other nations can develop more informed, effective, and nuanced approaches to cannabis regulation.

Scroll to Top